Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Income: 2010-2025

Historic Non Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $86.2 million.

  • Ligand Pharmaceuticals' Non Operating Income rose 1009.15% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 146.02%. This contributed to the annual value of -$54.9 million for FY2024, which is 206.19% down from last year.
  • Ligand Pharmaceuticals' Non Operating Income amounted to $86.2 million in Q3 2025, which was up 3,002.05% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Non Operating Income registered a high of $110.5 million during Q1 2024, and its lowest value of -$109.6 million during Q4 2024.
  • In the last 3 years, Ligand Pharmaceuticals' Non Operating Income had a median value of $2.8 million in 2025 and averaged $6.5 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 2,348.45% in 2023, then surged by 1,009.15% in 2025.
  • Ligand Pharmaceuticals' Non Operating Income (Quarterly) stood at -$19.8 million in 2021, then surged by 323.33% to $44.2 million in 2022, then plummeted by 53.76% to $20.5 million in 2023, then slumped by 635.83% to -$109.6 million in 2024, then soared by 1,009.15% to $86.2 million in 2025.
  • Its last three reported values are $86.2 million in Q3 2025, $2.8 million for Q2 2025, and -$14.0 million during Q1 2025.